Press Contact

PPTA staff is available to assist the news media on a daily basis.

Mat Gulick
Director, Global Communications
Office: +1.443.458.4669
Fax: +1.410.263.2298

Media and Information

PPTA News

PPTA Highlights Importance of Patient Access to Plasma Protein Therapies +

On July 16, the Plasma Protein Therapeutics Association (PPTA) submitted comments following the Trump administration’s “American Patients First” drug policy blueprint. In any discussions impacting the ability of individuals living with rare, chronic, and life-threatening diseases, PPTA remains steadfast to its mission to promote the availability of and access to safe and effective plasma protein therapies for all patients in the world.
Read More
Statement on Romanian Competition Council +

To our big surprise representatives from the Romanian Competition Authority arrived at our offices in Brussels on June 26 and were joined by Belgian police and the Belgian Competition Authority. The investigators were interested to know whether there was a coordinated effort to restrict supply of immunoglobulin therapies to the Romanian market for the purposes of pressuring the government to exempt these therapies from the “claw back” tax. PPTA cooperated fully with the investigators.
Read More
Joint pharmaceutical industry statement on the Commission’s proposal for a Regulation on health technology assessment (HTA) +

The pharmaceutical industry represented by AESGP¹, EFPIA², EUCOPE³, EuropaBio⁴, Medicines for Europe and PPTA⁵ – henceforth referred to as ‘the pharmaceutical industry’ – generally welcomes the European Commission (EC)’s Proposal for a Regulation on HTA⁶. We understand the scope of the joint clinical assessments foreseen in the proposal is limited to medicinal products subject to the centralised marketing authorisation, and exempting generic, biosimilar and non-prescription medicines⁷.
Read More